BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases

Cancer

Volumn 104, Issue 12, 2005, Pages 2807-2816

  Pal, Tuya ^a,b   Permuth Wey, Jenny ^a,b   Betts, Judith A ^a   Krischer, Jeffrey P ^a,b   Fiorica, James ^a,b   Arango, Hector ^c   LaPolla, James ^d   Hoffman, Mitchell ^b   Martino, Martin A ^b   Wakeley, Katie ^b   Wilbanks, George ^a,b   Nicosia, Santo ^a,b   Cantor, Alan ^a,b   Sutphen, Rebecca ^a,b  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c Morton Plant Hospital   (United States)

^d Bayfront Med Center St Petersburg   (United States)

Author keywords

BRCA1 and 2 mutations; Familial; Genetics; Ovarian neoplasms; Population based; Risk assessment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; FAMILY HISTORY; FEMALE; GENE CLUSTER; GENE FREQUENCY; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC COUNSELING; GENOTYPE PHENOTYPE CORRELATION; GERM LINE; HUMAN; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE; OVARY CARCINOMA; PRIORITY JOURNAL; BREAST CANCER; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; GENETIC SCREENING; GENETIC VARIABILITY; HETEROZYGOTE; MIDDLE AGED; MUTATIONAL ANALYSIS; PREVALENCE; RISK ASSESSMENT; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; CONFIDENCE INTERVALS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, BRCA1; GENES, BRCA2; GENETIC COUNSELING; GENETIC PREDISPOSITION TO DISEASE; GENETIC SCREENING; HUMANS; INCIDENCE; MIDDLE AGED; MUTATION; NEOPLASM INVASIVENESS; OVARIAN NEOPLASMS; PEDIGREE; PROBABILITY; PROGNOSIS; RISK ASSESSMENT; SURVIVAL RATE;

EID: 29144509766     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21536     Document Type: Article

References (43)

1. American Cancer Society. Cancer facts and figures 2005, vol. 2005. Atlanta: American Cancer Society, 2005.
2. Narod S, Ford D, Devilee P, et al. Genetic heterogeneity of breast-ovarian cancer revisited. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995;57:957-958.
3. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16:2417-2425.
4. Bewtra C, Watson P, Conway T, Read-Hippee C, Lynch HT. Hereditary ovarian cancer: a clinicopathological study. Int J Gynecol Pathol. 1992;11:180-187.
5. Whittemore AS. Characteristics relating to ovarian cancer risk: implications for prevention and detection. Gynecol Oncol. 1994;55:S15-S19.
6. Risch HA, McLaughlin JR, Cole DE, et al. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. Am J Hum Genet. 2001;68:700-710.
7. Anton-Culver H, Cohen PF, Gildea ME, Ziogas A. Characteristics of BRCA1 mutations in a population-based case series of breast and ovarian cancer. Eur J Cancer. 2000;36:1200-1208.
8. Sekine M, Nagata H, Tsuji S, et al. Mutational analysis of BRCA1 and BRCA2 and clinicopathologic analysis of ovarian cancer in 82 ovarian cancer families: two common founder mutations of BRCA1 in Japanese population. Clin Cancer Res. 2001;7:3144-3150.
9. Takahashi H, Behbakht K, McGovern PE, et al. Mutation analysis of the BRCA1 gene in ovarian cancers. Cancer Res. 1995;55:2998-3002.
10. Stratton JF, Gayther SA, Russell P, et al. Contribution of BRCA1 mutations to ovarian cancer. N Engl J Med. 1997;336:1125-1130.
11. Berchuck A, Heron KA, Carney ME, et al. Frequency of germline and somatic BRCA1 mutations in ovarian cancer. Clin Cancer Res. 1998;4:2433-2437.
12. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med. 2001;345:235-240.
13. Malander S, Ridderheim M, Masback A, et al. One in 10 ovarian cancer patients carry germ line BRCA1 or BRCA2 mutations: results of a prospective study in southern Sweden. Eur J Cancer. 2004;40:422-428.
14. Menkiszak J, Gronwald J, Gorski B, et al. Hereditary ovarian cancer in Poland. Int J Cancer. 2003;106:942-945.
15. Matsushima M, Kobayashi K, Emi M, et al. Mutation analysis of the BRCA1 gene in 76 Japanese ovarian cancer patients: four germline mutations, but no evidence of somatic mutation. Hum Mol Genet. 1995;4:1953-1956.
16. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2 and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178:670-677.
17. Van Der Looij M, Szabo C, Besznyak I, et al. Prevalence of founder BRCA1 and BRCA2 mutations among breast and ovarian cancer patients in Hungary. Int J Cancer. 2000;86:737-740.
18. Khoo US, Ngan HY, Cheung AN, et al. Mutational analysis of BRCAl and BRCA2 genes in Chinese ovarian cancer identifies 6 novel germline mutations. Hum Mutat. 2000;16:88-89.
19. Bjorge T, Lie AK, Hovig E, et al. BRCA1 mutations in ovarian cancer and borderline tumours in Norway: a nested case-control study. Br J Cancer. 2004;91:1829-1834.
20. Majdak EJ, De Bock GH, Brozek I, et al. Prevalence and clinical correlations of BRCA1/BRCA2 unclassified variant carriers among unselected primary ovarian cancer cases-preliminary report. Eur J Cancer. 2005;41:143-150.
21. Rafnar T, Benediktsdottir KR, Eldon BJ, et al. BRCA2, but not BRCA1, mutations account for familial ovarian cancer in Iceland: a population-based study. Eur J Cancer. 2004;40:2788-2793.
22. Ozols RF, Rubin SC, Thomas G, Robboy S. Epithelial ovarian cancer. In: Hoskins WJ, Perez CA, Young RC, editors. Principles and practice of gynecologic oncology. Philadelphia: Lippincott-Raven Publishers, 1997:919-986.
23. World Health Organization. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
24. Aitken J, Bain C, Ward M, Siskind V, MacLennan R. How accurate is self-reported family history of colorectal cancer? Am J Epidemiol. 1995;141:863-871.
25. Love RR, Evans AM, Josten DM. The accuracy of patient reports of a family history of cancer. J Chron Dis. 1985;38:289-293.
26. Novakovic B, Goldstein AM, Tucker MA. Validation of family history of cancer in deceased family members. J Natl Cancer Inst. 1996;88:1492-1493.
27. Schneider KA, DiGianni LM, Patenaude AF, et al. Accuracy of cancer family histories: comparison of two breast cancer syndromes. Genet Test. 2004;8:222-228.
28. Frank TS, Deffenbaugh AM, Reid JE, et al. Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals. J Clin Oncol. 2002;20:1480-1490.
29. Petrij-Bosch A, Peelen T, van Vliet M, et al. BRCA1 genomic deletions are major founder mutations in Dutch breast cancer patients. Nat Genet. 1997;17:341-345.
30. Unger MA, Nathanson KL, Calzone K, et al. Screening for genomic rearrangements in families with breast and ovarian cancer identifies BRCA1 mutations previously missed by conformation-sensitive gel electrophoresis or sequencing. Am J Hum Genet. 2000;67:841-850.
31. [No authors listed.] The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet. 2000;67:207-212.
32. Rohlfs EM, Puget N, Graham ML, et al. An Alu-mediated 7.1 kb deletion of BRCA1 exons 8 and 9 in breast and ovarian cancer families that results in alternative splicing of exon 10. Genes Chromosomes Cancer. 2000;28:300-307.
33. Ward BC, Hendrikson CA, Gaglio T, Scholl T. Identification of a novel 26 kb deletion in BRCA1 haplotype pair analysis [abstract]. Am J Hum Genet. 2002;71(4 Suppl):249.
34. Goldgar DE, Easton DF, Deffenbaugh AM, Monteiro AN, Tavtigian SV, Couch FJ. Integrated evaluation of DNA sequence variants of unknown clinical significance: application to BRCA1 and BRCA2. Am J Hum Genet. 2004;75:535-544.
35. Petrucelli N, Lazebnik N, Huelsman KM, Lazebnik RS. Clinical interpretation and recommendations for patients with a variant of uncertain significance in BRCA1 or BRCA2: a survey of genetic counseling practice. Genet Test. 2002;6:107-113.
36. Werness BA, Ramus SJ, DiCioccio RA, et al. Histopathology, FIGO stage, and BRCA mutation status of ovarian cancers from the Gilda Radner Familial Ovarian Cancer Registry. Int. J Gynecol Pathol. 2004;23:29-34.
37. Piek JM, Torrenga B, Hermsen B, et al. Histopathological characteristics of BRCA1- and ARG42-associated intraperitoneal cancer: a clinic-based study. Family Cancer. 2003;2:73-78.
38. Werness BA, Ramus SJ, Whittemore AS, et al. Histopathology of familial ovarian tumors in women from families with and without germline BRCA1 mutations. Hum Pathol. 2000;31:1420-1424.
39. Ramus SJ, Fishman A, Pharoah PD, Yarkoni S, Altaras M, Ponder BA. Ovarian cancer survival in Ashkenazi Jewish patients with BRCA1 and BRCA2 mutations. Eur J Surg Oncol. 2001;27:278-281.
40. Lu KH, Cramer DW, Muto MG, Li EY, Niloff J, Mok SC. A population-based study of BRCA1 and BRCA2 mutations in Jewish women with epithelial ovarian cancer. Obstet Gynecol. 1999;93:34-37.
41. Gotlieb WH, Friedman E, Bar-Sade RB, et al. Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors. J Natl Cancer Inst. 1998;90:995-1000.
42. Cass I, Baldwin RL, Varkey T, Moslehi R, Narod SA, Karlan BY. Improved survival in women with BRCA-associated ovarian carcinoma. Cancer. 2003;97:2187-2195.
43. Boyd J, Sonoda Y, Federici MG, et al. Clinicopathologic features of BRCA-linked and sporadic ovarian cancer. JAMA. 2000;283:2260-2265.